Basic Information
Gyala Therapeutics is developing next-generation immunotherapies for the treatment of hematological cancers with unmet needs. Its lead program, GYA01, is a first-in-class CAR-T therapy targeting CD84, a protein overexpressed in AML, T-ALL, and other blood cancers.
Gyala Therapeutics S.L.
Barcelona,Catalonia,Spain
less than 15 people
January 01, 2020
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios